The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) [1] was introduced in 2007 in an attempt to standardize international terminology and to categorize morphological criteria in fine-needle aspirations (FNAs) from patients with thyroid nodules. TBSRTC establishes six diagnostic categories for FNA results and assigns a malignancy risk and recommendations for patient management for each category. [1] Global studies of the incorporation of TBSRTC in diagnostic algorithms for patients with thyroid nodules have concluded that TBSRTC reduces unnecessary thyroidectomies while also ensuring the quality of thyroid malignancy detection. [2] Thyroid surgery can be associated with multiple complications, such as postoperative thyroid hormone imbalance, hypoparathyroidism, recurrent laryngeal nerve injury, bleeding, or infection; thus, there has been an effort to limit unnecessary surgery in asymptomatic patients with benign lesions. [3] Although studies have concluded that the Bethesda criteria appropriately stratify malignancy risk in thyroid nodules, [4] [5] [6] [7] controversy continues to exist regarding their accuracy and reliability in decision-making. [8] [9] [10] [11] The reasons behind this controversy are variability in the prevalence of cancer in the population studied, the inherent variability in the interpretation of cytology, and bias in the patient selection for surgery.
FNA at our institution in two arms: a retrospective arm from histopathology records of patients who had undergone thyroid surgery and a prospective arm where patients were evaluated by a single endocrinologist and if chosen to undergo thyroid surgery.
Settings and design
This study was conducted with a retrospective arm (collection of data from hospital records) and a prospective cohort of consecutive patients who underwent fine-needle aspiration cytology (FNAC) by a single endocrinologist.
MateRials anD MethoDs

Retrospective arm Study site
A retrospective registry review of the patients who underwent thyroid surgeries from January 2012 to December 2014 at Mazumdar Shaw Cancer Centre was performed, and details of final histopathology and prior FNA were collected.
Study population and study design
This is a retrospective review of patient records.
Time frame
This study was conducted from January 2012 to December 2014.
Inclusion criteria
Patients who had thyroid surgery at our institution and prior FNA of the thyroid nodule reported in Bethesda format are included in the study. Slides of FNA reports not conforming to the Bethesda format were reviewed by the author (NR) and reported in the Bethesda classification.
Exclusion criteria
Patients in whom the FNA was done outside or not reported in standardized Bethesda format (with no slides available for review) were excluded from the study. Patients who underwent thyroid surgery without prior thyroid nodule FNA were excluded from the study. Patients with multiple nodules and a lack of clarity from the report on the exact nodule that was sampled were excluded from the study. Patients with thyroid cancer diagnosis made from lymph node FNAC were also excluded from the study.
Methods
Data were collected from medical and electronic records and tabulated in case program. Data of patient characteristics, nodule size and location, FNA method (ultrasound-guided versus blind), cytology, and their final pathology were collected. Incidental microscopic thyroid cancers (<1 cm) were not categorized as malignant, and the actual histology of the nodule that was biopsied was taken into account. Lesions described as follicular neoplasm of uncertain malignant potential were considered to be benign for study purpose.
Prospective arm
• 
Intervention
A regular discussion between the endocrinologist and the cytopathologist took place in all the cases in the prospective arm, and the sonographic risk stratification of the thyroid nodule was provided to the cytopathologist.
Approval
The study was approved by our hospital's Ethics Committee.
Statistical analysis used
Continuous variables were reported in mean (standard deviation [SD]), median, and range. The reporting percentages of each Bethesda category and the percentage of malignancy in each category were calculated and compared with national studies. The results were compared using the two-sample t-test between percents (Microsoft Excel). P <0.05 was considered statistically significant.
Results
Retrospective arm
We analyzed 166 thyroid nodule data who had final histopathology; the mean (±SD) age of the patients in the data set was 40 ± 3.5 years (range: 16-72) with 79% females. Among the FNA performed at our institution, 28% (n = 46) were performed under ultrasound guidance by the radiologist, and 57% (n = 94) were performed blindly by the pathologist.
The mean age of the studied patients was 40 ± 13.5 years with 79% of them being women. Benign pathology was detected in 57% (n = 96) and malignant in 43% (n = 70). The results are summarized in Table 1 . As we can note, there was a significantly higher prevalence of malignancy in Bethesda Category 1 (33%) and 2 (16%) compared to literature reports.
When we analyzed the patients with Bethesda Category 2 with malignant histopathology, we noted that the mean size of these nodules was 5.95 ± 2.9 cm and they were more likely to cystic nodules. It is possible that inadequate sampling, less sonographic guided needle aspiration, and cystic papillary thyroid carcinomas might have contributed to the high prevalence of malignancy in Bethesda 2.
Prospective arm
246 FNAC aspirates were assessed prospectively, which included 198 females (80%), with mean (SD) age of 44 ± 13 years. Patients with thyroid bed lesions and lymph node aspirate (n = 8) were excluded from further analysis. A total of 77 nodules (32%) had final histopathology assessment out of which 45 nodules (58%) were malignant and 32 nodules (42%) were benign. The Bethesda category of the FNAC results and the prevalence of malignancy in each category have been presented in Table 1 . The rates of nondiagnostic cytology dropped from 11% to 5% (P = 0.05).
None of the patients categorized as Bethesda 1 or 2 who underwent surgery (n = 17) had thyroid cancer (P < 0.01). We noted that there was increase in numbers reported as Bethesda category 2 (38%-43%) and 6 (7%-11%) which are definitive categories of benign or malignant nodules, respectively (P = 0.31 and P = 0.17, respectively). There was a decline in numbers of Category 4 and 5 (13%-9% in Category 4 (P = 0.2) and 12%-3% in Category 5 (P < 0.01)), thus reducing the rates of diagnostic hemithyroidectomies.
The reporting prevalence of Category 3 increased from 19% to 28% (P = 0.03). The rates of malignancy in all the categories between the two arms are compared in Table 1 and compared with national literature in Tables 2a and b . We did not have a single case of false negative (malignant pathology reported as benign on cytology) reporting in Category 2 in our prospective arm compared to 16% in our retrospective arm (P < 0.01) and an average of 2.1%-7.5% in rest of the literature. While our malignancy rates of Category 3 increased from 38% to 50% (P = 0.01), this was on par with the national average of 47%. It is likely that the Category 3 patients chosen to be sent for surgery in the prospective group were likely to have "high-risk" sonographic pattern. On the contrary, our malignancy rates of Category 4 (follicular neoplasm) dropped from 52% to 36% (P < 0.01) (national average of 26%) indicating that sonography may not help distinguish between follicular adenoma (n = 7), carcinoma (n = 2), or follicular variant papillary thyroid cancer (n = 2). Our predictive value of malignancy in Category 5 and 6 was much better than national averages (66% and 99.7%, respectively) at 100%.
DisCussion
This exercise of standardizing the procedure of a single person performing the sonography and FNAC and regular discussion with the pathologist in providing them the risk stratification of the thyroid nodules based on American Thyroid Association classification helps in two areas. One it has significantly reduced the numbers of malignancy in the Category 2 (false negative rates). The rates of malignancy in Category 2 have ranged from 2.1% to 7.5% in most of the other Indian studies. We had an extremely high rate of malignancy in Bethesda 2 of 16% in our retrospective arm, but this reduced to 0% in the prospective arm. The other impact the intervention had was the combined rates of Bethesda 4 and 5 reduced significantly (P < 0.01) while it increased number of cases being called under Category 2 and 6 (54% versus 45% P = 0.07) and still retaining the 100% specificity. This ensures that some of the borderline cases are not labeled as Category 4 or 5 and reduces the rates of diagnostic hemithyroidectomy for these patients with thyroid cancer, and a complete thyroid surgery with neck dissection is performed in the first setting.
Our rates of malignancy in Category 3 and 4 are much higher than the international experiences indicating a referral bias as well as a bias of the treating physician/surgeon in referring specific patients with Category 3 with either clinical suspicion or sonographic suspicion for surgery. The scope of molecular testing in patients with Category 3 and 4 to "rule in" or "rule out" malignancy is still at infancy stages in India. At this point of time in patients in either of these categories, either a repeat FNAC or diagnostic hemithyroidectomy helps in further management. Sonographic risk stratification can better help in choosing patients for surgery. A patient with a low-risk nodule (5%-10% or < 5%) can be carefully followed up, however, if the nodule risk is 10%-15% or greater can probably be referred for surgery.
In a country like India, where there is a dearth of experienced thyroid surgeons, thyroid surgery carries a significant risk of hypoparathyroidism and recurrent laryngeal nerve injury and more importantly making the neck difficult to access in patients who need further surgeries. It is important to utilize the sonography and FNAC results in the best possible way in the evaluation of thyroid nodules. A regular interaction between the endocrinologist, sonologist, and cytopathologist helps the team triage patients better, with more patients with malignancy referred for surgery and follow patients with benign diagnosis without surgery. 
ConClusions
A team approach to thyroid nodules in the risk stratification of thyroid nodules helps in reduce inadequate sampling (Bethesda 1), reduce false-negative rates in Bethesda 2, reduce the prevalence of reporting in Bethesda Category 4 and 5, and increase more definitive reporting (Bethesda 2 and 6) without losing specificity. This helps avoiding unnecessary diagnostic surgery for benign nodules and subject patients with malignant nodules to more complete surgery in the initial setting.
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